4//SEC Filing
Shukla Sath 4
Accession 0000950170-25-014850
CIK 0001701108other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 8:31 PM ET
Size
10.1 KB
Accession
0000950170-25-014850
Insider Transaction Report
Form 4
Shukla Sath
CEO & President
Transactions
- Award
Common Stock
2025-02-03+751,407→ 1,892,216 total - Sale
Common Stock
2025-02-05$0.78/sh−6,139$4,788→ 1,886,077 total - Sale
Common Stock
2025-02-05$0.78/sh−42,786$33,373→ 1,843,291 total - Sale
Common Stock
2025-02-05$0.78/sh−106,408$82,998→ 1,736,883 total
Footnotes (4)
- [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022.
- [F3]The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023.
- [F4]The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
Related Parties
1- filerCIK 0001782817
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 8:31 PM ET
- Size
- 10.1 KB